U.S. Induced Pluripotent Stem Cells (iPSCs) Market, By Model Type (ECM-Patterned PAA/ PDMS Substrates, Microgroove PDMS Substrates, Strained Membranes, 3D Sacffolds, Free-Floating Hydrogel Contructs, and EHTS), Material (Natural Hydrogel-Based Cardiac Models and Synthetic Fibrous Cardiac Models), Cell Source (Skin Cells and Blood Cells), Dimensional Type (2D and 3D), Application (Production of New Cardiac Tissue to Replace Tissue Destroyed by Infraction or Other Diseases, Heart Failure, Ischemic Heart Disease, Arrhythmia, Cardiomyopathies, Valvular Heart Disease, Heart Disease Screening, and Others), End Use (Pharmaceutical & Biotechnology Companies, Academic and Government Research Institutes, Contract Development & Manufacturing Organizations, and Others), Distribution Channel (Direct Tender and Retail Sales) – Industry Trends and Forecast to 2031.
U.S. Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Insights
The key factors fueling the expansion of the market is the increasing technological advancements in the regenerative medicine. Rising government initiatives and funding policies is driving the market's expansion. In addition, the expanding applications in drug discovery will open up more business potential for the market.
The major restraint impacting the market is adherence to strict regulatory guidelines. The opportunities for the market are the increasing adoption of stem cell therapy.
The U.S. induced Pluripotent Stem Cells (iPSCs) market is expected to gain market growth in the forecast period of 2024 to 2031. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.7% in the forecast period of 2024 to 2031 and is expected to reach USD 488.42 million by 2031 from USD 218.87 million in 2023.
U.S. induced Pluripotent Stem Cells (iPSCs) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Model Type (ECM-Patterned PAA/ PDMS Substrates, Microgroove PDMS Substrates, Strained Membranes, 3D Sacffolds, Free-Floating Hydrogel Contructs, and EHTS), Material (Natural Hydrogel-Based Cardiac Models and Synthetic Fibrous Cardiac Models), Cell Source (Skin Cells and Blood Cells), Dimensional Type (2D and 3D), Application (Production of New Cardiac Tissue to Replace Tissue Destroyed by Infraction or Other Diseases, Heart Failure, Ischemic Heart Disease, Arrhythmia, Cardiomyopathies, Valvular Heart Disease, Heart Disease Screening, and Others), End Use (Pharmaceutical & Biotechnology Companies, Academic and Government Research Institutes, Contract Development & Manufacturing Organizations, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S.
|
|
Market players Covered
|
Corning Incorporated, Lonza, MIMETAS, CN Bio Innovations Ltd, 3D BIOTEK LLC, Axol Bioscience Ltd., and REPROCELL Inc., among others
|
Market Definition
Adult somatic cells can be used to make induced Pluripotent Stem Cells (iPSCs)—a form of stem cell (such as skin cells or blood cells). These cells have been rewired to become pluripotent, or more such as embryonic stem cells, in the past. As iPSCs can differentiate into multiple bodily cell types, they are useful for various research applications, disease modeling, regenerative therapy, and drug discovery. Typically, the process of creating iPSCs entails inserting particular genes or factors into adult cells, which causes them to undergo a developmental clock reset and take on traits akin to those of embryonic stem cells.
U.S. Induced Pluripotent Stem Cells (iPSCs) Market Dynamics
This section deals with understanding the market drivers, restraints, opportunities, and challenges. All of this is discussed in detail below:
Drivers
- Technological Advancement in Regenerative Medicine
The developments in regenerative medicine are a major factor in the U.S. induced Pluripotent Stem Cell (iPSC) market's explosive expansion. Researchers and clinicians are investigating novel therapeutic approaches to address a range of debilitating conditions as regenerative medicine advances because of their extraordinary capacity to differentiate into diverse cell types, which may replace or repair damaged tissues. Regenerative medicine's guiding principles of restoring normal function and promote healing are in line with the adaptability of iPSCs, which enables the development of precise and personalized treatments. Thus, the need for induced Pluripotent Stem Cell (iPSCs) in the US is directly fueled by the increased focus on regenerative medicine applications like tissue engineering and organ regeneration. The market is positioned as a major player in advancing transformative therapeutic solutions for a variety of medical conditions and the growing utility of induced Pluripotent Stem Cell (iPSCs). The objectives of regenerative medicine are in line with the capacity of induced Pluripotent Stem Cell (iPSCs) to differentiate into particular cell types needed for tissue repair and regeneration, offering a potent platform to address medical treatment.
- Expanding Applications in Drugs Discovery
The market for induced Pluripotent Stem Cells (iPSCs) in the U.S. is largely driven by the growing uses of iPSCs in drug discovery induced Pluripotent Stem Cells (iPSCs) provide a more physiologically relevant and human-specific platform for testing possible therapeutic compounds, which gives them a distinct advantage in the drug development process. Induced Pluripotent Stem Cells (iPSCs) can differentiate into a variety of cell types that closely resemble to human cell type, in contrast to traditional cell lines. This makes it possible for scientists to develop cellular models that are specific to a given disease, providing a more realistic depiction of human biology and disease pathology. As a result, to screen drug candidates more efficiently and increase the chance of discovering compounds with higher clinical success, pharmaceutical companies, and research institutions are increasingly integrating iPSCs into their drug discovery processes. The market is expanding due to the potential of induced Pluripotent Stem Cells (iPSCs) to advance drug discovery efforts through their versatility in generating disease models and their capacity to recapitulate complex cellular interactions.
Opportunity
- Increasing Interest of Personalized Medicine
Personalized medicine is one of the promising areas in health research, and patients are increasingly showing interest for customized drugs with better results and fewer side effects. Personalized medicine has potential to tailor the therapy with high safety margin and best response. This trend is largely driven by genome sequencing improvements. The move toward personal healthcare results in changes in the manufacturing of medicines. Manufacturers are moving from creating small molecule to combination of small molecule and gene therapies. Sponsors are focusing on replacing inefficient large scale batch production with investment in new technology and producing personalized drugs.
Although induced Pluripotent Stem Cells (iPSCs) can differentiate into many cell types, representing a patient's unique genetic composition and illness profile, they present a special benefit in personalized medicine. iPSCs (Induced Pluripotent Stem Cells) provide the means to generate patient-specific cell lines in the context of regenerative medicine, which facilitates the development of tailored therapies and accurate drug testing. Various sources of stem cells including mesenchymal stem cells and induced pluripotent stem cells have been considered in targeted therapies. Induced pluripotent stem cells have been introduced as appropriate approach for personalized cell therapies.
Restraints/Challenges
- Safety Concerns and Technical Difficulties
One of the main obstacles to the widespread use of induced Pluripotent Stem Cell (iPSCs) is their technical nature. Practical application of (iPSCs) is hampered by their complex nature, which includes the requirement for accurate differentiation into distinct cell types and maintaining consistent quality. A cautious approach is adopted by researchers and industry stakeholders due to the challenges of maintaining reproducibility, scaling up production, and addressing safety concerns. The rate of induced Pluripotent Stem Cell (iPSC) adoption in therapeutic and commercial settings is constrained by the significant research and development investments necessary to overcome these technological obstacles. Thus, achieving a thorough comprehension and resolution of these technological challenges is essential to realizing the full potential of induced Pluripotent Stem Cell (iPSCs) in a variety of medical applications.
- High Cost Associated with Stem Cell Therapies
Stem cell therapies are defined as treatment for medical conditions which involve the use of any type of human stem cells including induced pluripotent stem cells for allogenic and autologous therapies. A significant portion of the total cost is attributed to the complex process of iPSC creation, differentiation into distinct cell types, quality control procedures, and eventual therapeutic application. The cost is increased by a number of factors, including specialized laboratory equipment, highly qualified labor, stringent testing procedures, and regulatory compliance.
The requirement for customized therapies with patient-specific iPSCs raises the costs even more, adding to the complexity and expenditures. Many patients find these novel therapies financially unaffordable due to insurance coverage restrictions and the absence of reimbursement schemes.
The methods for generating stem cells, differentiating them into certain cell types, and guaranteeing their safety and effectiveness for therapeutic usage must first be thoroughly researched and developed. This phase frequently calls for large expenditures on scientific supplies, machinery, and skilled labor. The prices increase even more if the treatment intends to use induced stem cells particular to each patient. The process of creating and handling cells that are specific to each patient necessitates customized procedures and quality assurance, adding to the costs and duration involved.
Recent Developments
- In June 2023, WCG Clinical., one of the world's leading providers of solutions to improve the quality, efficiency and safety of clinical trials, recently announced a partnership with Mint Medical to use the Mint Lesion radiology platform in oncology research. Mint Lesion software is used for standardized and computerized review of medical imaging according to defined protocols, guidelines and workflows. Through this partnership, WCG combines clinical trial management solutions: workflows, quality systems, imaging solutions, technology and a broad network of reviewers with Mint Lesion's validated read-ready platform, structured reporting and site-specific workflows. a best-in-class solution for oncology education. The combination of WCG and Mint Medical offers an effective solution to the market
- In 2023, CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA. Such an award helped the company to cater to more customers globally
- In April 2023, 3D Biotek is relocating to 33 Technology Drive, Warren, NJ 07059. The market release for the fully automatic 3D Cell Expansion System is scheduled for the first quarter of 2023
- In May 2021, Lonza introduced the Nucleofector Platform 2.0, its most anticipated version. Primordial cells and pluripotent stem cells are among the hardest cells to transfect, yet Nucleofector Technology has been the most successful non-viral cell transfection technique for more than 20 years. The next generation 4D-Nucleofector Platform now offers flexibility and the same reliable performance with even greater simplicity of use thanks to an improved core unit and even more user-friendly software. This has aided the business in diversifying its line of products
U.S. Induced Pluripotent Stem Cells (iPSCs) Market Scope
The U.S. induced Pluripotent Stem Cells (iPSCs) market is categorized into seven notable segments based on model type, material, cell source, dimension type, application, end use, and distribution channel. The growth amongst these segments will help you analyze major industry growth segments and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Model Type
- ECM-Patterned PAA/PDMS Substrates
- Microgroove PDMS Substrates
- Strained Membranes
- 3D Scaffolds
- Free-Floating Hydrogel Contructs
- EHTS
On the basis of model type, the U.S. induced Pluripotent Stem Cells (iPSCs) market is segmented into ECM-Patterned PAA/PDMS substrates, microgroove PDMS substrates, strained membranes, free-floating hydrogel constructs, 3D scaffolds, and EHTS.
Material
- Natural Hydrogel-Based Cardiac Models
- Synthetic Fibrous Cardiac Models
On the basis of material, the U.S. induced Pluripotent Stem Cells (iPSCs) market is segmented into natural hydrogel-based cardiac models and synthetic fibrous cardiac models.
Cell Source
- Skin Cells
- Blood Cells
On the basis of cell source, the U.S. induced Pluripotent Stem Cells (iPSCs) market is segmented into skin cells and blood cells.
Dimensional Type
- 2D
- 3D
On the basis of dimensional type, the U.S. induced Pluripotent Stem Cells (iPSCs) market is segmented into 2D and 3D.
Application
- Production of New Cardiac Tissue to Replace Tissues Destroyed by Infraction or Other Diseases
- Heart Failure
- Ischemic Heart Disease
- Arrythmia
- Cardiomyopathies
- Valvular Heart Disease
- Heart Disease Screening
- Others
On the basis of application, the U.S. induced Pluripotent Stem Cells (iPSCs) market is segmented into heart failure, arrythmia, ischemic heart disease, cardiomyopathies, valvular heart disease, production of new cardiac tissue to replace tissues destroyed by infarction or other diseases, heart disease screening, and others.
End Use
- Pharmaceutical & Biotechnology Companies
- Academic and Government Research Institutes
- Contract Development & Manufacturing Organizations
- Others
On the basis of end use, the U.S. induced Pluripotent Stem Cells (iPSCs) market is segmented into pharmaceutical & biotechnology companies, academic and government research institutes, contract development & manufacturing organizations, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the U.S. induced Pluripotent Stem Cells (iPSCs) market is segmented into direct tender and retail sales.
Competitive Landscape and U.S. Induced Pluripotent Stem Cells (iPSCs) Market Share Analysis
U.S. induced Pluripotent Stem Cells (iPSCs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the U.S. induced Pluripotent Stem Cells (iPSCs) market.
Some of the major market players operating in the market are Corning Incorporated, Lonza, MIMETAS, CN Bio Innovations Ltd, 3D BIOTEK LLC, Axol Bioscience Ltd., and REPROCELL Inc., among others.
SKU-